Which four types of people are not suitable for taking larotrectinib (Vitakai) and risk warnings

Larotrectinib is mainly metabolized by the liver, so it is not suitable for patients with severe hepatic insufficiency or active liver disease. If such patients use larotrectinib, the drug may accumulate in the body, increase the burden on the liver, cause adverse reactions such as elevated liver enzymes, jaundice, and even severe liver damage. For patients who must use this drug, the dosage needs to be adjusted under the guidance of a doctor, and liver function indicators are regularly monitored to ensure the safety of the drug and to detect potential risks in a timely manner.

Larotrectinib taken by pregnant women may have adverse effects on the fetus, including developmental abnormalities or teratogenesis, so its use during pregnancy is strictly prohibited. At the same time, female patients should take effective contraceptive measures during treatment to avoid unwanted pregnancy. Larotrectinib is also not recommended for breastfeeding women because the drug may pass into the baby's body through breast milk, posing potential risks to the baby's health. In these groups, other safe treatment options should be chosen based on physician recommendations.

There are significant risks associated with the use of larotrectinib in patients with known hypersensitivity to larotrectinib or its excipients. Anaphylaxis may manifest as rash, itching, difficulty breathing, and in severe cases, anaphylactic shock. If allergic symptoms occur, the medication should be stopped immediately and corresponding treatment measures should be taken. Doctors should inquire in detail about the patient's allergy history before prescribing medication, evaluate the safety of the medication based on individual circumstances, and choose other treatments to reduce risks if necessary.

Patients with severe heart failure, cardiac arrhythmias, or severe renal impairment should use larotrectinib with special caution. Drugs may have certain effects on heart and kidney function, increasing the risk of adverse reactions. Therefore, in such patients, electrocardiogram, blood pressure and renal function indicators should be closely monitored, and the dose should be adjusted or medication suspended in a timely manner based on the monitoring results. At the same time, patients should pay attention to the occurrence of any abnormal symptoms and communicate with their doctors in a timely manner to ensure safe and effective treatment.

Reference link:https://www.drugs.com